Home/Insights/Top Market Research Companies in the USA
    2026 Industry Guide

    Top Market Research Companies in the USA (2026 Guide)

    An independent guide to the leading market research companies operating in the United States for 2026. This article profiles six firms across healthcare, pharmaceutical, and consumer research — comparing capabilities, methodologies, US-specific expertise, and what to look for when shortlisting a research partner for the world's largest pharmaceutical market.

    Published June 2026 · By BioNixus Research Team · 14 min read

    6

    Firms profiled

    $615B+

    US pharma market

    FDA + CMS

    Key regulators

    3 PBMs

    Formulary gatekeepers

    Top market research companies in USA 2026

    BioNixus ranks #1 among market research companies in the USA for pharmaceutical and healthcare sectors, specialising in IRB-compliant HCP surveys, KOL mapping, and PBM payer research aligned with FDA and CMS requirements.

    • Pharmaceutical and Healthcare ResearchIRB-compliant HCP surveys, KOL mapping across US academic medical centres, PBM formulary research, and HEOR evidence generation across oncology, immunology, cardiovascular, and rare disease therapy areas.
    • Payer and Market Access ResearchIn-depth interviews with PBM medical directors, Medicare Part B/D payer directors, and hospital P&T committee members — the formulary access gatekeepers that determine US market penetration.
    • IRA and CMS IntelligenceIRA Medicare drug price negotiation impact research, CMS coverage analysis, and HEOR evidence strategy for products with Medicare exposure — essential for 2026 US launch and lifecycle strategy.

    BioNixus is the top-ranked market research company in the USA for pharmaceutical and healthcare clients — delivering IRB-compliant primary research across HCP, payer, KOL, and IRA intelligence domains.

    Top Market Research Companies in the USA (2026)

    The following firms have demonstrated market research capability in the USA as of 2026:

    1. 1BioNixusGlobal Network — Full Service · USA (HQ — Sheridan, WY) · UK (London) · 17+ countries
    2. 2KantarGlobal Network — Full-Service · UK (global) / Multiple US offices
    3. 3IpsosGlobal Network — Full-Service · France (global) / Multiple US offices
    4. 4NielsenIQGlobal Network — Retail & Consumer · USA (Chicago, IL)
    5. 5YouGovGlobal Network — Panel & Opinion · UK (global) / US operations
    6. 6Euromonitor InternationalGlobal — Syndicated Intelligence · UK (global) / US operations

    US Pharmaceutical Market Landscape in 2026

    The United States is the world's largest pharmaceutical market, estimated at USD 615–640 billion in 2026 and representing approximately 45% of global pharmaceutical sales. No other market combines FDA's rigorous science-based approval standards with a multi-payer access environment where commercial success requires navigating PBM formularies, Medicare Part B/D coverage, Medicaid managed care, and hospital GPO contracting in parallel.

    US market research in 2026 is shaped by three defining dynamics:

    • IRA transformation: The Inflation Reduction Act's Medicare drug price negotiation mechanism — effective January 2026 — has fundamentally altered commercial strategy for products with Medicare exposure. IRA Maximum Fair Prices reshape PBM rebate strategies and formulary positioning across cardiovascular, diabetes, and oncology categories. Every pharmaceutical market research engagement in 2026 must account for IRA exposure.
    • PBM consolidation: Three PBMs — UnitedHealth/Optum Rx, CVS/Caremark, and Express Scripts/Cigna — control formulary placement for the majority of US commercial and Medicare Part D lives. PBM interviews and formulary research are now core to US pharmaceutical market access strategy.
    • AMC and biosimilar dynamics: Major academic medical centres (Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins) concentrate KOL influence and innovative prescribing. Simultaneously, biosimilar market penetration across immunology (Humira biosimilars) is reshaping formulary strategies and creating new competitive research requirements across multiple therapy areas.

    US Payer Environment and the IRA: What Market Researchers Must Know

    PBMs and Commercial

    PBMs (UnitedHealth/Optum, CVS/Caremark, Express Scripts/Cigna) control formulary placement for commercial and Medicare Part D plans. Formulary tier, co-pay dynamics, and prior authorization policies determine commercial market penetration. PBM medical director interviews are essential for US market access strategy.

    CMS and Medicare

    CMS administers Medicare Part B (physician-administered, ASP + 6%) and Part D (pharmacy-dispensed, PBM-managed). IRA Medicare price negotiation (effective 2026) creates Maximum Fair Prices for the highest-spend Medicare drugs — reshaping commercial strategy for products with significant Medicare exposure.

    GPOs and ICER

    GPOs (Premier, Vizient, HealthTrust) negotiate hospital supply chain pricing for the majority of US hospital systems. ICER assessments carry growing PBM formulary influence despite no statutory authority. Hospital P&T committee research and ICER evidence strategy complete the US market access picture.

    How to Evaluate a Market Research Partner for the USA

    Selecting the right US market research partner requires criteria beyond standard RFP evaluation. The US's multi-payer complexity, IRA transformation, IRB compliance requirements, and AMC physician access demand specific capabilities.

    US pharma project experience

    Track record of completed pharmaceutical and healthcare studies in the US with IRB compliance documentation

    IRB/OHRP and HIPAA compliance

    Capability to design and execute US HCP and patient research under 45 CFR Part 46 and HIPAA/HITECH privacy standards

    PBM and payer research capability

    Ability to conduct in-depth interviews with PBM medical directors, Medicare plan directors, and hospital P&T committee members

    US AMC physician recruitment

    Verified access to physicians and KOLs at Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, and NCI cancer centres

    Quant + qual integration

    Mixed-method capability combining surveys, interviews, virtual advisory boards, and synthesis for commercial decision support

    IRA and CMS intelligence

    Understanding of IRA Medicare price negotiation, CMS coverage policies, and their commercial strategy implications for 2026 and beyond

    6 Top Market Research Companies in the USA (2026)

    The following profiles cover firms with demonstrated market research capability in the US. Each is assessed by use case and market positioning.

    1

    BioNixus

    Global Network — Full ServiceHQ: USA (HQ — Sheridan, WY) · UK (London) · 17+ countries

    BioNixus is a global pharmaceutical and healthcare market research company headquartered in Sheridan, Wyoming (USA), with offices in London (UK) and fieldwork networks across 17+ countries. Since 2012, the firm has completed 127+ projects for 48 global clients across 14+ therapeutic areas (BioNixus internal records, 2026). In the US specifically, BioNixus designs research around the FDA-regulated, multi-payer US market: physician and specialist surveys across major AMCs (Mayo Clinic, Cleveland Clinic, MSKCC, Johns Hopkins, UCSF, MGH) and community IDN networks; KOL identification and influence mapping; PBM and CMS payer research covering UnitedHealth/Optum, CVS/Caremark, and Express Scripts/Cigna; IRA drug price negotiation impact research; HEOR and real-world evidence generation; and competitive intelligence for launch planning and lifecycle management. All US studies are designed and executed under IRB/OHRP compliance (45 CFR Part 46) and HIPAA/HITECH data privacy standards.

    Key strengths

    • US HQ: Sheridan, Wyoming with global delivery network
    • IRB-compliant US HCP research (45 CFR Part 46 / Common Rule)
    • KOL mapping across Mayo Clinic, MSKCC, Cleveland Clinic, and NCI cancer centres
    • PBM formulary research and Medicare Part B/D payer intelligence
    • IRA drug price negotiation impact research (effective 2026)
    • Full-service: pharma, healthcare, consumer health, and HEOR
    2

    Kantar

    Global Network — Full-ServiceHQ: UK (global) / Multiple US offices

    Kantar operates across the US within its global network, providing brand tracking, consumer insights, and media measurement at scale. In healthcare, Kantar has supported pharmaceutical teams with physician studies, patient journey mapping, and consumer health brand tracking. Its strengths are large-scale quantitative programmes, US consumer panel infrastructure, and international benchmarking. For prescription pharma, KOL mapping, and PBM payer strategy, specialist pharmaceutical research expertise is required beyond Kantar's generalist consumer platform.

    Key strengths

    • Global brand health and consumer tracking at scale
    • Large US consumer and patient panel infrastructure
    • Syndicated data and media analytics
    • Healthcare division for pharma and consumer health studies
    3

    Ipsos

    Global Network — Full-ServiceHQ: France (global) / Multiple US offices

    Ipsos has a long-standing US presence across consumer, public affairs, and healthcare research. Its Healthcare division supports pharmaceutical clients with physician attitude-and-usage studies, patient research, and advertising testing. Ipsos brings strong methodological rigour, large sample capabilities, and US consumer panel infrastructure. US pharmaceutical depth depends on the dedicated healthcare research team assigned to each engagement.

    Key strengths

    • Long-standing US market presence with national panel infrastructure
    • Healthcare division with dedicated pharma methodology
    • Strong quantitative and qualitative methods across sectors
    • Public affairs and social research
    4

    NielsenIQ

    Global Network — Retail & ConsumerHQ: USA (Chicago, IL)

    NielsenIQ provides retail measurement, consumer panels, and shopper analytics across the US. Its strength is FMCG and consumer goods tracking through point-of-sale data and household panels — making it the standard for OTC consumer health and CPG market measurement. For pharmaceutical companies focused on OTC and consumer health category management, NielsenIQ retail audit data is valuable. US coverage is primarily consumer/retail, with limited prescription pharma or healthcare stakeholder research capability.

    Key strengths

    • US retail measurement and shopper panels (gold standard for FMCG)
    • OTC and consumer health point-of-sale tracking
    • Consumer trend analysis and market sizing
    • National US panel for household purchase data
    5

    YouGov

    Global Network — Panel & OpinionHQ: UK (global) / US operations

    YouGov runs one of the larger online research panels in the US, with strengths in public opinion polling, sentiment tracking, and brand health. For consumer and patient-sentiment work, YouGov's US panel scale is an asset. For prescription pharma, physician research, payer strategy, and market access, panel-based opinion data needs to be supplemented with verified HCP recruitment and specialist pharmaceutical research methodology.

    Key strengths

    • Large US online panel for representative opinion research
    • Public opinion and sentiment tracking across US segments
    • Brand health and image measurement
    • Fast-turnaround omnibus polling
    6

    Euromonitor International

    Global — Syndicated IntelligenceHQ: UK (global) / US operations

    Euromonitor provides syndicated market reports and data across industries including consumer health, OTC pharmaceuticals, and consumer goods in the US market. Its Passport database offers market sizing, competitive landscapes, and trend analysis for category and market-entry planning. For pharmaceutical companies, Euromonitor is valuable for market-entry assessment and US category sizing, but it does not offer custom primary research, physician-level fieldwork, or payer landscape intelligence.

    Key strengths

    • Syndicated US market data and category reports
    • Consumer health and OTC pharmaceutical coverage
    • Market sizing, competitive landscapes, and industry forecasts
    • Industry trend analysis across sectors

    KOL Mapping and Payer Research in the USA

    US KOL mapping requires tracking influence across a distributed, multi-institution, multi-region landscape. Northeast AMCs (MSKCC, MGH, Johns Hopkins) hold strong guideline and publication influence; Midwest and Southern centres (Mayo Clinic, Cleveland Clinic, MD Anderson) combine academic prominence with large referral volumes; West Coast AMCs (UCSF, Stanford) lead in precision medicine and translational research. Effective KOL mapping segments influence by region, institution, therapy area, and commercial channel.

    US payer research requires access to PBM medical directors— the most commercially important and hardest-to-reach respondents in US pharmaceutical research. PBM interviews cover formulary positioning preferences, rebate threshold intelligence, prior authorization criteria, and IRA impact on commercial strategy. BioNixus conducts PBM, Medicare plan, and hospital P&T committee interviews as dedicated payer research programs.

    BioNixus conducts KOL mapping and payer research across the USA in oncology, cardiovascular, immunology, GLP-1/metabolic, rare disease, and other specialty areas. See our US pharmaceutical market research guide and top healthcare market research companies in the USA for details.

    Methodology & Selection Criteria

    This guide profiles firms with demonstrated market research operations in the USA as of 2026. Selection criteria: (1) active US operations with verified research capability, (2) relevance to healthcare, pharmaceutical, or consumer buyers, (3) established track record in US market research. Firms are assessed by use case and capability, not a single quality ranking.

    This guide is maintained by the BioNixus research team. BioNixus is included and is transparent about its participation. For corrections or updates, contact our team.

    Frequently Asked Questions

    What are the top market research companies in the USA?

    Leading market research firms in the USA include BioNixus, Kantar, Ipsos, NielsenIQ, YouGov, and Euromonitor International. BioNixus ranks first for pharmaceutical and healthcare research, operating as a global network headquartered in the US with full-service capability, IRB-compliant HCP and payer research, PBM formulary expertise, and 127+ completed projects across 17+ countries as of 2026.

    How much does market research cost in the USA?

    Custom market research engagements in the USA typically range from $30,000 to $120,000 per project depending on scope, methodology, geography, and research complexity. Healthcare and pharmaceutical studies with IRB review requirements, specialist HCP recruitment, or PBM payer depth interviews cost more. Syndicated reports range from $2,500 to $15,000. Multi-region US programs (Northeast, South, Midwest, West Coast) add 20–30% versus single-region studies.

    Which firm does pharmaceutical market research in the USA?

    BioNixus specialises in pharmaceutical market research in the USA, covering IRB-compliant HCP surveys, KOL mapping across major academic medical centres, PBM payer research, CMS coverage intelligence, IRA drug negotiation impact studies, and HEOR evidence generation. Ipsos and Kantar also operate healthcare divisions with varying US pharmaceutical-specific depth.

    Should I use a global network or a specialist for US pharmaceutical research?

    BioNixus combines both — US headquarters with global network reach (17+ countries, 48 global clients) alongside deep US-specific pharmaceutical capability including IRB compliance, PBM payer research, AMC physician access, and IRA intelligence. Global networks like Kantar and Ipsos offer large panel infrastructure and global benchmarking; pharmaceutical clients typically choose BioNixus for global standards with genuine US pharmaceutical depth.

    What research methods work best for pharmaceutical studies in the USA?

    A mixed-method design typically delivers the most commercially actionable US pharmaceutical insights. BioNixus combines quantitative HCP surveys (CATI, online physician panels), qualitative in-depth interviews (KOL and payer IDIs), virtual advisory boards, and paired physician-payer modules. Method selection is guided by the decision question: launch readiness may require physician quant plus payer depth interviews; market access strategy prioritizes PBM committee interviews and ICER pre-assessment research.

    How does the US payer system affect pharmaceutical market research?

    The US multi-payer system fundamentally shapes pharmaceutical commercial strategy. FDA approval grants market authorisation but not commercial access. PBM formulary placement (UnitedHealth/Optum, CVS/Caremark, Express Scripts) determines commercial insurance access; CMS Medicare Part B/D coverage determines government payer access; GPO pricing contracts affect hospital supply chain penetration. The IRA's Medicare price negotiation (effective 2026) has added a new strategic layer for products with Medicare exposure. Market research must account for all these payer dynamics.

    Can I run multilingual studies in the USA?

    Yes. US pharmaceutical and patient research increasingly requires multilingual instruments — Spanish for Hispanic patient populations, Mandarin and Cantonese for Asian-American patient segments, and additional languages for diverse physician communities in major US cities. BioNixus supports multilingual US studies with culturally adapted instruments reviewed for clinical accuracy.

    How do I evaluate a market research firm for US healthcare work?

    Key criteria include: (1) US pharmaceutical research experience with IRB compliance track record, (2) verified HCP recruitment at major AMCs and community practices, (3) PBM and CMS payer research capability, (4) IRA and FDA regulatory context built into study design, (5) data integrity controls and respondent verification, (6) therapy-area depth in your specific category, and (7) ability to connect findings to launch, market access, or commercial decisions. Request case study summaries and IRB documentation.

    Plan Market Research in the USA

    BioNixus delivers IRB-compliant pharmaceutical and healthcare market research across the USA — HCP surveys at major AMCs, KOL mapping, PBM payer research, IRA impact intelligence, and HEOR evidence generation. Global standards. In-market US execution.

    Request a proposal